Author: Diego Moricoli
A recent study published in Biomolecules by researchers from the Italian Institute of Health and “Sapienza” University of Rome open new perspectives for the treatment of Chronic Lymphocytic Leukemia (CLL). The research, conducted with the support of Diatheva, led to the development of a new immunocytokine, scFvB1IL15, which has been shown to enhance the activity of NK (natural killer) cells against tumor cells.
Understanding CLL and NK Cells
CLL is a blood disease characterized by the accumulation of malignant B lymphocytes. NK cells play a crucial role in the immune response against tumors, but in CLL their function is often impaired. scFvB1IL15 is an innovative molecule that combines an antibody specific for NK cells and interleukin 15 (IL-15), a cytokine that stimulates NK cell activity.
Study Results: Restoring NK Cell Function
The results of the study show that scFvB1IL15 is able to restore the ability of NK cells to kill tumor cells in patients with CLL. The construct could be also explored in other disorders that cause NK dysfunctions or in adoptive transfer protocols to improve and sustain NK cells expansion and activation, contribuiting to the development of NK-based immunotherapies strategies.
DIATHEVA: A leading CDMO
Diatheva is highly experienced Contract Development and Manufacturing Organization (CDMO) with over 20 years of experience in the biotechnology sector. Diatheva collaborates closely with research institution and clients, offering tailored support and guidance throughout their research journey. We are committed to fostering strong partnerships that drive scientific progress. Diatheva is the resourceful partner that makes you fill the gap between your application and the lack of research tools for it.
Diego Moricoli is a Responsible of Downstream Production at Diatheva with over 20 years of experience in managing R&D activities and GMP manufacturing. His expertise spans biochemistry and pharmacology, with a strong focus on innovation in bioprocessing.